Evidence map›Paper›PMID 31583357›Full record

ReviewPain reports

Risks of harm with cannabinoids, cannabis, and cannabis-based medicine for pain management relevant to patients receiving pain treatment: protocol for an overview of systematic reviews.

Ian Gilron, Fiona M Blyth, Louisa Degenhardt, Marta Di Forti, Christopher Eccleston, Simon Haroutounian, Andrew Moore, Andrew S C Rice, Mark Wallace

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pain reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 4 countries.

Ian GilronDepartment of Anesthesiology and Perioperative Medicine, Kingston General Hospital, Queen's University, Kingston, ON, Canada.
Fiona M BlythUniversity of Sydney Centre for Education and Research on Ageing, Concord Repatriation General Hospital, Concord, New South Wales, Australia.
Louisa DegenhardtNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.
Marta Di FortiSocial, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Christopher EcclestonCentre for Pain Research, The University of Bath, Bath, United Kingdom.
Simon HaroutounianDivision of Clinical and Translational Research, Department of Anesthesiology, Washington University Pain Center, Washington University School of Medicine, St Louis, MO, USA.
Andrew MooreNuffield Department of Clinical Neurosciences, University of Oxford, Pain Research, The Churchill, Oxford, United Kingdom.
Andrew S C RicePain Research Group, Department Surgery and Cancer, Faculty of Medicine, Imperial College London, London, United Kingdom.
Mark WallaceDepartment of Anesthesiology, University of California San Diego, San Diego, CA, USA.
Churchill Hospital · GBImperial College London · GBNational Institute for Health Research · GBQueen's University · CAUniversity of Bath · GBUniversity of California, San Diego · USUniversity of Sydney · AUUNSW Sydney · AUWashington University in St. Louis · US

Funding

Using existing data to understand and ameliorate risk in opioid agonist therapyR01DA044170 · NIDA · UNIVERSITY OF NEW SOUTH WALES · PI DEGENHARDT, LOUISA · 2017 to 2019
$641k
NIDA NIH HHS R01 DA044170
6 · The paper itself

Abstract

introductionWith the increasing availability of cannabis and cannabinoids and their potential utility for pain treatment, there is a growing need to evaluate the risk-benefit considerations of cannabinoids for the management of pain. As part of the IASP Cannabis and Cannabinoids Task Force, this protocol describes a planned overview of systematic reviews summarizing the risks of harm with cannabinoids that are relevant to patients receiving pain treatment.

methodsThis overview will involve literature searches of several databases and a defined search strategy that will target systematic reviews or meta-analyses of cannabinoids where harms are the primary focus. Data extraction will include various features of the cannabinoid(s) and the harm(s) being studied as well as other methodological features of each included systematic review. Methodological quality of each included review will be assessed using AMSTAR-2 as well as compliance with the PRISMA harms checklist. Prospero registration pending. DISCUSSION: The broad overview of reviews defined by this protocol is expected to synthesize available good quality evidence of harms that will help inform risk-benefit considerations about the use of cannabinoids for pain management.

Indexed as

Adverse effectsAdverse eventsCannabinoidsCannabisClinical trialsHarmsPain management

Identifiers

PMID31583357
PMCPMC6749892
OpenAlexW2947678535

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.